化疗在晚期非小细胞肺癌治疗中的地位和价值被引量：1

The Status and Value of Chemotherapy in Advanced Non-small Cell Lung Cancer

导出

摘要化疗于晚期非小细胞肺癌治疗依然具有举足轻重的作用。以IPASS研究为代表的一系列靶向治疗与化疗头对头对比研究,也证实了化疗依旧是EGFR野生型及突变未明患者一线治疗的首要选择。DELTA研究及CTONG0806研究结果则表明二线治疗中化疗比靶向治疗疗效更优。而LUX-LUNG3/6研究生存数据则表明21外显子突变患者可能更适合于一线化疗。总而言之,化疗是晚期非小细胞肺癌治疗全程管理中不可或缺的。 Today,chemotherapy for advanced non-small cell lung cancer is still playing an important role. Represented by IPASS study, a series of RCT research between targeted therapy and chemotherapy confirmed that the chemotherapy remains the first choice for first-line patients with wild type EGFR or uncertain mutation. DELTA and CTONG0806 study results showed that the response with second-line chemotherapy was superior to that with targeted therapy. LUX- LUNG3/6study results showed that patients with 21 exon mutation might be more suitable first-line chemotherapy. To sum up,chemotherapy is indispensable to the whole course of management for advanced non-small cell lung cancer.

作者陈申马锐

机构地区大连医科大学研究生院辽宁省肿瘤医院大连医科大学临床肿瘤学院

出处《中国肿瘤》 CAS 2015年第9期737-741,共5页 China Cancer

关键词非小细胞肺癌靶向治疗化疗 non-small cell lung cancer targeted therapy chemotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献28

1Siegel RL,Miller KD,Jemal A. Cancer statistics,2015 [J].CA Cancer J Clin,2015,65(1): 5-29.
2Bunn PA Jr. The expanding role of cisplatin in the treat- ment of non-small-cell lung cancer [J]. Semin Oncol, 1989,16(4 Suppl 6): 10-21.
3Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer [J]. Semin Oncol, 1989,16(2 Suppl 5): 27-33.
4Marino P,Pampallona S,Preat0ni A,et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature [J]. Chest, 1994,106(3): 861-865.
5Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346(2): 92-98.
6Kelly K,Crowley J,Bunn PA Jr,et al. Randomized phase m trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial [J]. J Clin Oncol,2001,19(13): 3210-3218.
7Scagliotti GV,De Marinis F,Rinaldi M,et al. Phase llI randomized trim comparing three platinum-based doublets in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2002,20(21): 4285-4291.
8Sandier A, Gray R,Perry MC ,et al. Paelitaxel-earboplatin alone or with bevacizumab for non-small-cell lung cancer [J]. N Engl J Med,2006,355(24): 2542-2550.
9Pirker R,Pereira JR,Szczesna A,et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase m trial [J]. Lancet,2009,373(9674): 1525-1531.
10Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ill study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with ad- vanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008,26(21): 3543-3551.